Ann: Creso signs distribution agreement in Switzerland - CannaQIX, page-15

The tie up with LGC is likely to have a great number of spin-offs in many many products and places, the Baltic Beer agreement being the first.

David Lenigas, LGC founder and Co-Chairman commented, “This is an excellent first venture with Creso Pharma.
The international hemp and cannabis infused beverage market is growing at astonishing rates and we are committed to becoming an active player in this exciting new market. Viru is already exporting their award winning beer to many countries around the world, and with Creso Pharma's scientific expertise, we look forward to working actively to create something of real value.”

He obviously sees value in aligning with CPH. And…

The Collaboration Agreement, which Creso and LGC expect to sign before December 31, 2017, will set out in detail the terms and conditions of their strategic alliance.

Not long to wait…

They are thinking big at the dawn of a enormous global industry…..

09 November 2017
Creso Pharma and LGC Capital Announce Strategic Alliance

Montreal, Québec, Canada and Perth, Australia – November 9, 2017 – Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”), and Swiss based pharmaceutical company, and Canadian listed LGC Capital Ltd. (“LGC”), jointly announce the formation of a new and exciting strategic alliance intended to create a vertically-integrated cannabis operation with a global footprint spanning cultivation, IP generation, innovative product development and commercialisation.

• In anticipation of the imminent launch of Creso’s first pioneering animal health product anibidiol in Switzerland and Lichtenstein as well as the upcoming launch of its human heath product cannaQIX in Q1 2018, Creso is looking to aggressively expand its market reach.
• LGC brings potential access to the highest quality, competitive supply of cannabis from southern Africa, a global logistics footprint and capability to introduce Creso’s innovative products to key markets of Canada and Africa and other regions within LGC’s growing global footprint.

• Creso and LGC will engage in developing sales and distribution of products jointly in Europe, Canada, Latin America, Africa, Japan and the Asia-Pacific region.
• Together, Creso and LGC will develop, produce and market innovative human and animal health solutions addressing the growing demand for cannabis and hemp-derived therapeutics, cosmetics, nutraceuticals and lifestyle products.
• The combination of LGC’s access to competitive-source cannabis with Creso’s Swiss-based expertise in product development and market access is intended to deliver significant added value for customers and consumers.
• The strategic alliance is designed to result in better access to high quality cannabis-based consumer products globally.